Alveolar bone is grown by stem cell injection, tooth regeneration is not a dream
Chinese doctors have developed new drugs, waiting for tooth regeneration
In desperation, they can only pull out the teeth one by one. Just when Ms. Wang felt painful, the Capital Medical University targeted one This new drug is recruiting volunteers for clinical research. After using the new drug, the teeth that Ms. Wang is about to loose and lose should be able to be saved.
This newly developed drug needs to be Inject at multiple intervals around the periphery, the entire medication process, each tooth only needs less than 2 minutes of injection time. After taking the medicine for half a year, the alveolar bone on the upper right of Ms. Wang actually grew 2 millimeters, the bleeding of the gums disappeared, and the teeth that had to be removed later were also saved. This miraculous new drug is called “dental mesenchymal stem cells.”
An academician of the Chinese Academy of Sciences developed this new drug Wang Songling and his team developed it after more than 20 years, and the new drug was born from the stem cells of wisdom teeth, deciduous teeth, and orthodontic teeth that were regarded as “waste”.
Periodontitis is an oral disease that is difficult to cure, and the resulting loosening and falling of teeth. The current treatment method only delays the progress of the disease.
In 2003, Wang Songling began to work on animals Tooth stem cell regeneration of biological tooth roots is the use of tooth stem cells to achieve the regeneration of human tooth roots. In 2006, their research results were collected and displayed in the permanent collection of the American Dental Museum. In 2010, the research results of Wang Songling’s team won the second prize of the National Science and Technology Progress Award. In 2018, the research results were also selected into the international dental trauma textbook.
October 2017, Beijing Food and Drug The Supervision Bureau accepted this new drug for clinical research experiments. This is also the first stem cell drug accepted since the promulgation of my country’s new stem cell management regulations. Currently, the new drug has entered the second phase of clinical trials. This new drug is one step closer to being available to the public.
The new drug for dental pulp mesenchymal stem cells is used To treat periodontitis and prevent tooth loss in the early stages, if tooth loss is caused by periodontitis, biological tooth root regeneration and whole tooth regeneration come in handy. At present, this research is becoming a reality in our laboratories. Tooth regeneration will no longer be a fantasy.
Hu Lei, Wang Songling’s student, has been in Wang Songling’s research group since 2011. Hu Lei told reporters that biological tooth root regeneration is like building the foundation of a house. As long as the tooth root regenerates, they can connect the crown, which is different from the current one. Dental implants are based on threaded nails. Biological tooth roots use stem cells to regenerate a tissue close to one’s own teeth to support the crown.
The effective rate has gone from less than 10% to nearly 50%. There are new methods for the treatment of liver cancer
According to the latest data released by the World Health Organization: 2020 Globally, there were 910,000 new cases of liver cancer and 830,000 deaths. And nearly half of these are from China, so on the rugged road to fight cancer, the clinical frontline scientists are doing their own efforts.
The 58-year-old Mr. Luo in 2013 Liver cancer was detected in a routine physical examination. Less than two years after the operation, the cancer cells had not been controlled, but had spread. Mr. Luo, who sought medical treatment everywhere to no avail, felt that his life was coming to an end. From the end of 2018, he participated in the clinical trial of drug combination therapy being conducted by Professor Xu Jianming of the General Hospital of the People’s Liberation Army.
Statistics show that more than 50% of hepatocellular carcinoma patients worldwide are in China. More than 80% of new-onset patients each year have no chance of surgery. The only available treatment drugs are molecular targeted drugs and PD-1 monoclonal antibodies. Unfortunately, the effective rate of treatment is only 5%~10%, 5 years The survival rate is only 10% to 18%.
Xu Jianming’s team began to study PD-1 orders in 2016 A new therapy against combined targeted drugs, immune checkpoint inhibitors combined with targeted drugs, has shown a “1+1 greater than 2” effect in the treatment of advanced liver cancer. After a phase of clinical research, the effective rate is close to 50%. The subsequent multi-center Phase II study showed that the effective rate of treating liver cancer patients was as high as 46%.
At the end of 2018, this research result was published in the internationally renowned medical journal “Clinical Cancer Research”. At present, this new treatment has been listed as the first-line standard treatment for advanced liver cancer by the 2020 Chinese Society of Clinical Oncology Liver Cancer Diagnosis and Treatment Guidelines.
Xu Jianming told reporters that pancreatic neuroendocrine tumors are malignant tumors Although the incidence is not high, the possibility of metastasis is great. In the past many years, drugs to treat this disease were developed by foreign institutions, and the clinical trials he led used drugs invented by the Chinese themselves.
In ten years, the drug Xu Jianming led the research has benefited more and more patients. Not only the effect is significant in pancreatic neuroendocrine tumors, but it has also been effectively verified in non-pancreatic neuroendocrine tumors. This small molecule targeted drug can easily cross the cell membrane, penetrate into the intracellular region of vascular endothelial cells, and act on the target inside the cell membrane. After the targeted drug is combined with the intracellular part of the trans-intracellular protein, the tumor tissue The formation of new blood vessels will be blocked, and the tumor will stop growing due to cutting off the blood nutrient supply channel.
After Ms. Zhao, who had been ill for 10 years, passed the treatment, The condition has basically stabilized. I have been a mother two years ago, and my work and life are on the right track. But for Xu Jianming, his scientific research hasn’t stopped here. Now he still has more than 40 clinical studies of drugs in his hands, waiting for him to explore and dig.
[Half-hour observation] Innovation: Making the impossible possible
In today’s program, we saw that scientists who stick to the clinical frontline, in order to relieve the pain of patients, For decades, they insisted on continuously climbing on the road of innovation. The new therapies and new programs they tempered in clinical practice are not only the magic weapon and weapon to overcome the disease, but also the hope for many patients to continue their lives. This year is the first year of the “14th Five-Year Plan” and the beginning of the new journey of building a modern socialist country in an all-round way. When drawing a blueprint for new development, the Party Central Committee placed the protection of the people’s health as a strategic priority for development, and the protection of the lives and health of the people is inseparable from the innovation of medical technology. We expect that in the new journey, the ecology of medical innovation will continue to improve, which will stimulate the vitality of innovation and creation, and ultimately allow the people to enjoy more of the tangible well-being brought by medical innovation.